Press Releases

Onxeo Announces Data Demonstrating High Patient Compliance and Acceptability of Validive® for Treatment of Severe Oral Mucositis — Onxeo offentliggør data, der viser et højt niveau af ordinationsoverholdelse og en god sikkerhedsprofil for Validive® til behandling af svær oral mucositis

Results Presented in Oral ePoster Presentation at ASTRO Annual Meeting 2015 Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology drugs, announced compliance and patient acceptability results from a global Phase 2 clinical trial demonstrating daily treatment application of Validive® (Clonidine Lauriad®), a mucoadhesive buccal tablet for…read more →

Onxeo Validive® Abstract Accepted for Oral Presentation at ASTRO Annual Meeting 2015 — Abstract for Onxeo Validive® accepteret til mundtlig præsentation ved ASTRO’s årsmøde 2015

Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology drugs, today announced that an abstract supporting the clinical evaluation of Validive® (Clonidine Lauriad®), a mucoadhesive buccal tablet developed for the prevention and treatment of chemo-radioation therapy-induced severe oral mucositis (SOM) in patients with head and neck cancer,…read more →

Onxeo announces evolution in the Board of Directors — Onxeo offentliggør ændring i bestyrelsen

Mr. Patrick Langlois is planning to step down from the chairmanship in early 2016 for personal reasons Mr. Joseph Zakrzewski is joining the Board and is expected to be appointed Non-Executive Chairman in 2016 Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative biopharmaceutical company specializing in the development of orphan oncology drugs, today announced…read more →

Onxeo announces positive DSMB recommendation for continuation of Livatag® ReLive study in HCC — Onxeo offentliggør positiv anbefaling fra DSMB om at fortsætte ReLive-studiet med Livatag® mod leverkræft

Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology drugs, today announced that it has received a unanimous recommendation from the Data Safety Monitoring Board (DSMB), the independent European board of experts that monitors the safety of the Livatag® Phase III trial, “ReLive”, to continue the study…read more →

Publication of a new letter to shareholders — Offentliggørelse af nyt aktionærbrev

Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology drugs, today announces the publication of its new letter to shareholders. This issue is devoted to our orphan oncology product Beleodaq®. You will find full information about the product, its key features and indications, as well as interviews…read more →

Decision in the litigation opposing Onxeo to the companies Eurofins and ABL – Afgørelse i retssagen mod Eurofins og ABL

Decision in the litigation opposing Onxeo to the companies Eurofins and ABL Recognition of  Eurofins’s debt to Onxeo resulting from the absence of payment of the option This debt is compensated by damages benefiting Eurofins None of the parties obliged to the payment of has to pay an indemnity towards the other Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an…read more →

Corporate Governance prize awarded by AGEFI: Onxeo receives “Silver Governance” for the second consecutive year

Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative biopharmaceutical company specialized in the development of orphan oncology drugs, has been awarded for the second consecutive year the “Silver Governance” in the small and midcap companies category at the Twelfth Annual Corporate Governance Awards held by the French financial magazine AGEFI on September 16, 2015. The Corporate Governance Prizes reward…read more →

Onxeo files application for key Livatag® patent — Onxeo indleverer ansøgning om vigtigt patent for Livatag®

Potential expansion of Livatag IP estate to extend commercial exclusivity through 2036 Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative biopharmaceutical company specialized in the development of drugs for orphan oncology diseases, today announced that it has filed an international patent application to protect the overall compound related to its primary liver cancer orphan oncology product Livatag®. The patent…read more →

Onxeo to present at InvestorDagen 2015 – Onxeo repræsenteret ved InvestorDagen 2015

Onxeo to present at InvestorDagen 2015 The largest Danish private investor event September 22, 2015, Radisson Blu Scandinavia Hotel, Copenhagen Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative biopharmaceutical company specialized in the development of drugs for orphan oncology diseases, will be presenting at InvestorDagen 2015, which will be held in Copenhagen, Denmark on September 22, 2015 at the…read more →

Publication of a Shareholders Letter – Offentliggørelse af nyhedsbrev til aktionærerne

Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology drugs, today announces the publication of a Shareholders Letter (1). This Shareholders Letter updates on major achievements of the first half of 2015 and on the company’s short and middle term catalysts. (1)    The Shareholders Letter is available on the website at: www.onxeo.com…read more →

Capital increase in Onxeo resulting from the exercise of share subscription options from employees

Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative biopharmaceutical company specialized in the development of orphan oncology drugs, has increased its share capital by a nominal amount of €4,357.50 following the issue of 830 shares each with a nominal value of €0.25 and resulting from the exercise of share subscription options from employees of the company. The new shares…read more →

Onxeo Reports First Half 2015 Business Update and Consolidated Accounts – Onxeo informerer om sine forretningsmæssige tiltag og resultatet for 1. halvår 2015

Livatag® Phase III trial in HCC: 50% of patients randomized Scientific recognition of Validive® and Beleodaq® preclinical and clinical data at ASCO Annual  Meeting and MASCC/ISOO International Symposium Sound financial position with €42.9 million cash  Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology drugs, today reported its consolidated half-year accounts as…read more →

Update on ReLive, Livatag® international phase III clinical trial in HCC – 50% patients randomized – Opdatering om ReLive, det internationale kliniske fase III-studie med Livatag® til behandling af leverkræft 50% patienter randomiseret

Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology drugs, updates on the clinical development status of ReLive , the Livatag® phase III trial  in the treatment of hepatocellular carcinoma. Livatag®, a new therapeutic approach for hepatocellular carcinoma Livatag® is based on the innovative « Transdrug ™ » technology  designed to formulate a chemotherapy (doxorubicin)…read more →

Meetings with the financial community during the 2nd semester of 2015 – Møder med finansverdenen i 2. halvår 2015

Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology drugs, announces its meetings with the investors and shareholders during the second semester 2015. September 16, 2015 11:30am: – Analyst and Investor Meeting 5:30pm: Audio/web conference September 22, 2015 InvestorDagen Radisson Blu Scandinavia Hotel – Copenhagen, Denmark October 7 & 8, 2015 European…read more →